February 2021 Simoa® Publications:

Neurology: Alzheimer’s Disease, Parkinson’s Disease, FTD, and ALS

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Cicognola, C, et al.
Alzheimers Res Ther. 2021;13:38

Alzheimer’s Disease

Link to Article

ApoE4 reduction with ASOs decreases neurodegeneration in a tauopathy model

Litvinchuk A, et al.
Ann Neurol. 2021

Alzheimer’s Disease

Link to Article

Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study

Brickman, AM, et al.
Alzheimers Dement. 2021 Feb 13

Alzheimer’s Disease

Link to Article

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

Ashton, NJ, et al.
Acta Neuropathol (2021).

Alzheimer’s Disease

Link to Article

Genetic study of young-onset dementia using targeted gene panel sequencing in Taiwan

Hsu, JL, et al.
Am J Med Genet B Neuropsychiatr Genet. 2021

Alzheimer’s Disease

Link to Article

High specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples

Arbaciauskate, M, et al.
Antibody Therapeutics. 2021

Alzheimer’s Disease

Link to Article

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Zetterberg, H and Blennow, K
Mol Neurodegeneration 16, 10 (2021)

Alzheimer’s Disease

Link to Article

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: An 8-year longitudinal study

Ye, R, et al.
Parkinsonism & Related Disorders. 2021;85:11-16

Parkinson’s Disease

Link to Article

Blood Biomarkers in Frontotemporal Dementia: Review and Meta-Analysis

Ntymenou, S, et al.
Brain Sci. 2021, 11(2), 244

Frontotemporal Dementia

Link to Article

Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation

Toft, A, et al.
Dement Geriatr Cogn Disord. 2021:1-6

Frontotemporal Dementia

Link to Article

February 2021 Simoa® Publications:

Neurology: Alzheimer’s Disease, Parkinson’s Disease, FTD, and ALS

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

ApoE4 reduction with ASOs decreases neurodegeneration in a tauopathy model

Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

Genetic study of young-onset dementia using targeted gene panel sequencing in Taiwan

High specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: An 8-year longitudinal study

Blood Biomarkers in Frontotemporal Dementia: Review and Meta-Analysis

Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation

Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives